healthcare

en
4,534 Members

Cards

Recommended

So sánh giữa tổ yến thô và yến tinh chế loại nào tốt?
Nên mua yến thô hay yến tinh chế, loại yến sào nào tốt cho sức khỏe nhất hiện nay? là những thắc mắc phổ biến trong thị trường yến sào. Những người thường xuyên sử dụng yến sào sẽ ít băn khoăn về các sản phẩm từ tổ yến tuy nhiên không ít chị em có sự hoang mang về món ăn cao cấp này. Yến sào là thực phẩm có giá trị cao không chỉ về dinh dưỡng mà còn đắt đỏ cho nên khi mua sản phẩm này về sử dụng cần tìm hiểu kỹ. Trên thị trường có nhiều loại sản phẩm được bày bán, về cơ bản có 2 loại chính sau đây: - Yến thô, một sản phẩm tổ yến nguyên chất 100%, do chưa qua công đoạn làm sạch nên giá trị dinh dưỡng cao tổ yến này được nhiều người mua về ăn , tuy nhiên khi mua loại này về dùng bạn phải tự tay làm sạch lông và cặn bẩn rồi mới có thể chế biến món ăn. Giá tổ yến thô hiện nay không quá cao và cũng dễ dàng mua được. - Yến tinh chế có hàm lượng dinh dưỡng thấp hơn so với yến thô nhưng giá lại cao hơn do chúng được xử lý và sấy khô nên chi phí cao hơn. Dù vậy loại này lại được dùng nhiều là do chúng tiện lợi cho người sử dụng, vì đã được làm sạch sẽ đẹp trắng tinh nên phù hợp để đem làm quà biếu tặng. Một món quà sức khỏe vô cùng quý giá nếu là sản phẩm yến chuẩn chất lượng. Nhưng thực tế thì luôn phũ phàng bởi mua yến tinh chế chứa nhiều rủi ro . loại yến này đang bị làm giả rất nhiều, bị pha trộn nhiều dẫn đến chất lượng kém thậm chí ảnh hưởng tới sức khỏe, vậy nên người tiêu dùng cần có sự cân nhắc kỹ trước khi mua. Nên lựa chọn sản phẩm từ các shop uy tín, có sự cam kết về chất lượng. Khi mua yến về bạn nên kiểm tra bằng cách ngâm nước lọc để xem tổ yến thật giả như thế nào Kết hợp chưng yến cùng Đông trùng hạ thảo Bhutan chuẩn ngon quá tuyệt vời cho sức khỏe. Tìm hiểu thêm các bài viết liên quan tới yến sào: yến cho bé dưới 1 tuổi https://thewingsviet.com/yen-cho-be-duoi-1-tuoi/
Thương hiệu ngũ cốc nào mang lại nhiều công dụng cho phụ nữ?
Bạn đã sử dụng ngũ cốc dinh dưỡng bao giờ chưa? nếu có thì bạn đánh giá loại ngũ cốc nào có nhiều công dụng tốt cho sức khỏe chị em phụ nữ. Để giải đáp thắc mắc này trước tiên chúng ta cần biết thêm thông tin về sản phẩm ngũ cốc. Trên thị trường hiện nay có hàng nghìn sản phẩm ngũ cốc các loại khác nhau, ngũ cốc dinh dưỡng cho cả gia đình, ngũ cốc tăng cân, ngũ cốc giảm cân, ngũ cốc minmin cho bà bầu , ngũ cốc dành cho người tiểu đưỡng, ngũ cốc dành cho chị em phụ nữ sau sinh... Mỗi loại ngũ cốc sẽ có những thành phần các hạt thực vật khác nhau và cách chế biến cũng khác nhau cho nên công dụng đương nhiên là khác nhau rồi. Thương hiệu ngũ cốc Lạc Lạc là một trong những sp mang lại nhiều công dụng cho sức khỏe không chỉ cho mẹ sau sinh mà còn tốt cho bà bầu. Ngũ cốc Nhà Cừu có tốt không là câu hỏi cũng được nhiều bà mẹ hỏi trong tuần qua, đây là bột ngũ cốc lợi sữa có tác dụng bổ sung sinh dưỡng cho cơ thể. Bên cạnh đó, còn có những sản phẩm ngũ cốc lợi sữa, ngũ cốc dinh dưỡng chất lượng tốt , được kiểm định chặt chẽ về an toàn vệ sinh thực phẩm. bạn có thể tìm hiểu thêm các thông tin về ngũ cốc để đưa ra sự lựa chọn tốt nhất. Xem thêm bột ngũ cốc lợi sữa mới hiện nay https://thewingsviet.com/ngu-coc-loi-sua-viet-loc/
Exercising Enhances The Probability Of Getting Slim
The mill worker does a wide array of exercising, from less active to quite difficult work. The researchers saw that calorie consumption was higher in staff in contact with a larger work desire, only for average-to-great degrees of exercising. The beneficial impact of participating in routine workouts training is impartial of weight loss. Physical exercise and diet regime are interrelated because ideal adaptation for the stress of exercising training generally needs a diet plan which is not enough a variety of nutrients and vitamins. Nevertheless, they will not use up more calories every day, an unexpected discovering that implicates the metropolitan children’s updated diet programs with their putting on weight. Although you are revving your pulse rate, like when working, fishing or cycling, you will likely rev your metabolic process. The Simple Promise may be the Business that companies the VivaSlim supplement beneath rigid security requirements to permit greater fat loss outcomes with a secure dose. The VivaSlim supplement is the anti-overweight solution that comes in liquid to assist healthier weight-loss to aid folks irrespective of their ages or gender. Natural Home Remedies That Will Help You Lose Tummy Fat Due to its stomach-cutting materials referred to as catechins, green tea leaf is the ideal cleansing drink to shed stomach fat. You should consider swapping the normal coffee with green tea leaf, as studies show 4 to 5 servings from the green tea are required to begin seeing the positive aspects. “The short response is that dropping abdominal fat needs a lifestyle change, and there is absolutely no fast solution. Whether you are overworked or stressed, persistent pressure might be one issue adding to tummy fat. Hence, the VivaSlim supplement allows you to attain a slim and hotter body by overcoming excess fat storage space in the body. The usage of herbal treatments to shed weight is not advised through the healthcare neighborhood due to the danger of toxicities and insufficient specialized medical performance. Moreover, natural remedies for losing weight can be a lasting therapy that may grow to be obsessive. Do not get herbal treatments if you have a long-term medication. A Bunch Of Cardiovascular WithOut Weight Training Exceeding 500 quality recipes, 150 exercise routines, and many skilled-well guided dish and exercise ideas, you will get support for all of your fitness and health quest. Studies have shown that localized fat reduction depends upon your gender (not your training session program!). If you pass by the 1000s of VivaSlim reviews online, the supplement’s credibility is guaranteed by dedicated consumers who may have noticed the results of its everyday use. With situps or other abdomen workouts, you happen to be tightening the stomach muscles but not getting rid of intra-belly fat. Research demonstrates that extra carb ingestion could cause belly fat, each visceral and subcutaneous. This complete VivaSlim review addresses your real concerns regarding the supplement. Stick to a frequent exercise schedule and consume a healthy diet plan, and you may discover a positive change within your weight with time. Spot Reduction And Fat Loss Shedding fat and muscle development are not mutually distinctive, and both of them are essential for enduring weight reduction and long-term physical fitness. We have a few pre-determined questions relating to the key topic of fat loss than muscle building soon after. Raising weight can boost muscles size, but it fails to make a significant difference regardless of whether subcutaneous body fat is situated into it. People who are a novice in weight training have a superior prospect of fairly speedy muscle mass gain. Many studies point towards the brilliance of weight training for fat reduction.
Interventional Radiology Products Market worth $14.1 billion by 2026
According to the new market research report "Interventional Radiology Products Market by type (Stents, Catheters, IVC Filter, Biopsy Needles, Embolization Devices, Accessories), Procedure Type (Angioplasty, Angiography, Thrombolysis, Embolization), Applications (Oncology) - Global Forecast to 2026", published by MarketsandMarkets™, the global market is projected to USD 14.1 billion by 2026 from USD 10.2 billion in 2021, at a CAGR of 6.6% during the forecast period. Browse in-depth TOC on "Interventional Radiology Products Market" 132 – Tables 39 – Figures 219 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=67681703 The Rising prevalence of chronic diseases, growing geriatric population, increasing demand for minimally invasive procedures and favorable reimbursement scenario for interventional radiology procedures are the major factors driving the growth of the market. The stent segment is expected to grow at the highest CAGR during the forecast period and also accounted for the largest share in 2020. Based on type, the interventional radiology products market is segmented into catheters, stents, inferior vena cava (IVC) filters, hemodynamic flow alteration devices, angioplasty balloons, thrombectomy systems, embolization devices, biopsy needles, accessories (contrast media, guidewires, balloon inflation devices, and other accessories), and other interventional radiology products (bone cements, nephrostomy tubes, and gastrostomy tubes). Stents account for the largest share of the market. The large share of this segment can be attributed to the growing number of angioplasty procedures performed globally and the increasing incidence of cardiac diseases and cancer. Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=67681703 North America was the largest regional market for the interventional radiology products market in 2020 The market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America was the largest regional market for market in 2020. The large share of the North American market can be attributed to the high prevalence of chronic diseases, growing geriatric population, increasing adoption of minimally invasive procedures, and the presence of key players in the region. However, the Asia Pacific interventional radiology products market is estimated to grow at the highest CAGR during the forecast period. The presence of emerging economies such as China, India, and South Korea, rising prevalence of chronic diseases, the growing demand for quality medical care, increasing healthcare spending and government initiatives, rising disposable income, growth in the medical device industries, and improvements in healthcare infrastructure in Southeast Asian countries are the major factors driving the growth of the market in the Asia Pacific. The global interventional radiology products market is consolidated. The prominent players operating in this market include Medtronic (Ireland), Boston Scientific Corporation (US), Becton, Dickinson and Company (US), Abbott (US), Cardinal Health (US), B. Braun Melsungen AG (Germany), Stryker (US), Terumo Medical Corporation (Japan), Cook Medical (US), Biosensors International Group, Ltd. (Singapore), Teleflex Incorporated (US), iVascular S.L.U. (Spain), Penumbra, Inc. (US), and BIOTRONIK SE & Co. KG (Germany).
What Impacted COVID-19 on Surgical Visualization Products ?
COVID-19 Impact on Surgical Visualization Products in Healthcare Industry The first case of the COVID-19 pandemic was found in Wuhan, China. This pandemic has influenced the whole planet with its major impacts on the economy and businesses across the globe. The COVID-19 spread worldwide in unprecedented ways due to its high infectious and contagious nature and lack of availability of its vaccine. As a result, the greatest medical challenge in the 21st century is yet to be faced by physicians worldwide. Though the emergence of the virus can be traced back to Asia, many European countries and the U.S. have been struck massively by the pandemic. The virus has spread across all regions ranging from North America, Europe, Asia-Pacific, Middle East, and Africa up to South America. The COVID-19 has been declared as a pandemic by WHO due to its increased spread across the globe. Various countries announced complete lockdown just after the declaration of COVID-19 as a pandemic, such as the U.S., India, Germany, and China, to protect them from spreading the disease. According to the weekly epidemiological report of 23rd August 2020 by WHO, a cumulative total of 23 million cases of Coronavirus have been reported globally, and 800,000 patients are dead due to the Coronavirus. Surgical visualization products are used to improve the quality of images of internal organs with greater resolution. They improve the surgical process and enhance communication between healthcare professionals, specialty clinics, and patients. 3D visualization technology’s incorporation in diagnostics has enabled easy inspection and visualization of organs in 360 views, thereby being the accurate and improved quality of surgery. Surgeons and healthcare professionals widely prefer surgical visualization to evaluate, inspect and treat internal organs from a distance from the target organs without incision. The rise in chronic diseases, advancement in surgical visualization, rising healthcare expenditure are acting as drivers for the global surgical visualization products market. The implications of COVID-19 have considerable influence on the surgical visualization products market. Various factors that indirectly influence the decline in medical surgery procedures include flight cancellations, travel bans, mass quarantine, growing panic among the population, and uncertainty about the future. IMPACT ON PRICE Delay associated with various types of limitations due to the pandemic faced by the manufacturers to fulfill the end product order, which has resulted in less availability of surgery devices in the market. The cost of available devices has increased with several factors. Also, due to the Coronavirus disease (COVID-19) pandemic, manufacturers are forced to find new contract manufacturers and suppliers to move manufacturing activities to different or new facility locations less impacted by the outbreak. If the COVID-19 continues to spread for prolonged period, then it is estimated that the demand for surgery devices will downgrade by top importer countries. Moreover, top surgical visualization product importers' countries such as the United States and Europe are primarily concentrating on dealing with Coronavirus (COVID-19); due to this reason, demand for these surgical visualization products are decreased from the United States followed by Italy. In current situations, the manufactures of surgical visualization products are facing difficulties with the existing component supplier or contract, manufacturers who are at risk or closed or not being able to fulfill supply requirements, due to challenges such as extended periods of shut down or workforce are responsible for price fluctuation of surgical visualization products. IMPACT ON DEMAND Coronavirus disease (COVID-19) is an infectious disease caused by a SARS-CoV-2 virus, while a large population is affected by this COVID-19 virus. Coronavirus disease (COVID-19) causes acute respiratory illness ranges from mild to severe pneumonia with respiratory failure. Nearly all the countries have taken initiative action under locked down and social distancing restrictions to minimize the spread of COVID-19. Sudden shrink took place in various surgeries due to affirmative restrictions. Reduction in surgeries across the globe is adversely affecting the on-demand of minimally invasive surgery devices. However, due to lockdown and social distancing restrictions, most of the patient pool prefers virtual visits through video calling or telehealth video visiting. In compliance with the Centers for Disease Control recommendations, the American College of Surgeons, the Brazilian Society of Plastic Surgery, and the American Society of Plastic Surgeons recommended postponing or canceling elective surgery. The goal of this recommendation is two-fold: first to minimize patient and visitor traffic in healthcare settings to reduce transmission between patients and healthcare workers and secondly, to preserve essential resources, especially hospital beds, critical care and ventilator supplies, and PPE critical to the safety of patients and healthcare professionals. Moreover, the decrease in the revenue of the key market players depicted in their quarterly results, such as Johnson & Johnson Services, Inc., among others, gave evidence of the decline in the demand for medical devices due to the emergence of the COVID-19 pandemic. For instance, · Johnson & Johnson Services, Inc., reported a decline of 10.5% in its medical devices net sales of the fourth quarter of 2020 compared to 2019. The reduction was largely motivated by the detrimental effects of the COVID-19 pandemic and the subsequent deferral to companies of medical procedures. IMPACT ON SUPPLY The COVID-19 pandemic has transformed various organizations’ business environments; supply availability has been hampered by many issues, including export and travel restrictions by some producing countries and lockdowns that have forced suppliers to (temporarily) shut down. Healthcare organizations have been firmly monitoring the supply chain with the assumption that the COVID-19 outbreak may adversely impact the supply chain of medical devices, including shortages of surgical visualization products or potential disruptions in its supply chains to minimize supply chain crises. For instance, · The Zimmer Biomet spine, dental and CMFT segment sales have a decrease of 10.3% and found a decline in total sales from USD 1,161.3 million in 2019 to USD 1,043.7 million in 2019. These decline in sales are due to disruption of the supply chain and change in the focus to COVID 19 Several organizations are looking forward to improving and diversifying supply chain models to manage such a crucial situation. A diversified supply chain model anticipated minimizing the export of medical devices and increasing end-to-end visibility. The resulting COVID-19 pandemic has shown the various ways for supply chain management, which may be effective within a remote working environment. STRATEGIC DECISIONS BY MANUFACTURERS A large pool of population affected by COVID-19 virus and spread been expanding across the world in the last few months. Various market players are creating new strategies to deal with the COVID-19 outbreak challenges. The companies are now opting for digital media such as telecommunication, mobile applications, webinars, and other digital media to support the patient required to tackle the pandemic situation and increase their revenue and growth. Moreover, to accomplish the market demand, small market players are utilizing the partnership agreement strategy. It is projected that these strategies are anticipated to escalate up the company revenue and its growth in the forecast period. For instance, · In September 2021, Smith & Nephew launched LENS 4K surgical imaging system, a state-of-the-art visualization platform designed for end-to-end 4K imaging, which has created a persistent revenue-generating path for the company. · In January 2016, CONMED Corporation completed the acquisition of privately-held SurgiQuest, Inc. This acquisition has strengthened company’s leadership in the market. Furthermore, for the economic recovery after the pandemic of COVID-19, the manufacturers of surgical visualization products have to adopt several types of strategic initiatives in terms of increasing R&D activities conduct numerous types of market surveys to know the current situation and mindset of consumers towards their need. The increasing R&D activities will help the manufacturers to launch the advanced equipment by knowing the advanced technology or need of the end user. CONCLUSION The market is expected to decline due to increased restrictions imposed by various governments leading to the closing of non-emergent healthcare facilities, including procedures such as surgery medical devices. The mass quarantined imposed by the government put a stop to transportation, international travel, among others which reduced the chances of such surgery. The market player has experienced decreasing customer demand for its products beginning in the second half of its first quarter of 2020. Thus, the COVID-19 pandemic has an adverse impact on the market, affecting the price, supply, and demand of surgical visualization products. However, in the crisis call, market players, government bodies, and healthcare organizations are working closely with healthcare professionals, customers, and patients to better public health. However, companies and government bodies exclusively concentrate on making the most effective and best contribution to control the spread of the virus and save lives. They are also ramping up the production of essential medication to a new level and ensuring that speed doesn’t affect or destroy the quality of products.
Significant Impact of COVID-19 on Dermal Fillers | Healthcare Industry
COVID-19 Impact on Dermal Fillers in Healthcare Industry In the city of Wuhan, China the coronavirus disease (COVID-19) outbreak was first experienced after that, coronavirus disease (COVID-19) has expeditiously spread across the globe, with a large number of cases having been reported worldwide. The coronavirus disease (COVID-19) pandemic is not only creating a health crisis but also affecting healthcare, economies, and the pharmaceutical sector as well as at their core. As COVID-19 is an infectious disease, its spread is endless; moreover, there is no specific and approved treatment for the coronavirus disease (COVID-19) on the other hand global dermal filler manufacturing companies are finding it difficult to manufacture and distribute products across borders due to lockdown, disrupted supply chains, and social distancing restrictions. Coronavirus pandemic has hit the healthcare systems across the globe due to high debt levels and already weak economies of the region. The implications of COVID-19 have considerable influence on the dermal fillers market are now it is starting to be felt. Various factors have an indirect influence on the decline of the dermal filler market as frontline healthcare professionals are involved in essential procedures and containment of COVID-19 spread. Moreover, flight cancellations, travel bans, mass quarantine along with growing panic among the population, and uncertainty about the future are some of the other factors involved. PRICE IMPACT Due to the pandemic, there is a delay associated with various types of limitations faced by the manufacturers to fulfill the end product order. However, according to the primary respondent from Gladerma Laboratories LLC, the company did not stop the manufacturing of the Restylane although the demand was normal during the pandemic. Also, due to the coronavirus disease (COVID-19) pandemic outbreak, manufacturers are forced to find new contract manufacturers and suppliers to move manufacturing activities to different or new facilities locations that are less impacted by the outbreak. The average cost of dermal filler is USD 652/per injection in 2019 which was decreased during COVID-19 due to a decrease in demand. IMPACT ON DEMAND In compliance with the recommendations of the Centers for Disease Control, the American College of Surgeons, the Brazilian Society of Plastic Surgery, and the American Society of Plastic Surgeons recommended postponing or canceling elective surgery. The goal of this recommendation is two-fold: first to minimize patient and visitor traffic in healthcare settings to reduce transmission between patients and healthcare workers and secondly, to preserve essential resources, especially hospital beds, critical care and ventilator supplies, and PPE critical to the safety of patients and healthcare professionals. · U.S.-based dermatologist told in an interview that before COVID they daily perform 10-20 procedures of fillers. However during COVID, they suggested their client delay the procedure before they get vaccinated and or after 1 month of being vaccinated. This also decreases the demand to some extent · According to American Academy of Facial Plastic and Reconstructive Surgery's (AAFPRS) while demand for facial plastic surgery procedures increased, the AAFPRS found that the demand for dermal filler decreased for the first time in years · There are several theories that denote the decrease in demand such as the use of mask have due to which faces are covered which delayed the demand of dermal filler procedures. · Some plastic surgeons saw a decrease in demand due to the shift of procedure as the dermal filler is temporary and stays for 3 to 4 years. However, plastic surgeries are permanent which decreases the demand for the product. This instance clearly indicated the negative impact on the demand of dermal filler product. However, Allergen Product Juvederm which is now the product of Abbvie got approval in 2019 and during the Revenue 2020 showed that the overall sale of Juvederm is USD 718 Million which is fragmented into USD 318 million of the U.S. and USD 400 million International. The above instance showed that the product demand decreased due to lockdown and fewer patient visits in the hospital or clinics. IMPACT ON SUPPLY The COVID-19 pandemic has transformed many organizations’ business environments. Supply availability has been hampered by a number of issues, including export and travel restrictions by some producing countries, and lockdowns that have forced suppliers to (temporarily) shut down. To minimize supply chain crises, healthcare organizations have been firmly monitoring the supply chain with the assumption that the COVID-19 outbreak may adversely impact on the supply chain of medical devices, including shortages of aesthetic & cosmetic surgery devices or potential disruptions in its supply chains. · Revance which is a U.S.-based manufacture of dermal fillers announced that they didn’t find an issue with the supply chain as they have their manufacturing plant in the U.S. only · However, the agreement with Teoxane SA for the production of RHA 2, 3, 4 has delayed the commercialization and supply of this product in the market. The company in the initial quarters of 2020 has stopped the manufacturing of RHA due to COVID-19 and deficiency of raw material STRATEGIC DECISIONS BY MANUFACTURERS A large pool of the population affected by this COVID-19 virus and its spread been expanding across the world for the last few months. In order to deal with the COVID-19 outbreak challenges, many dermal filler market players are creating new strategies. Also, to tackles the pandemic situation and increase the company revenue and growth, the company now opting for digital media such as telecommunication, mobile applications, webinars, and other digital media to support the patient requirement. Moreover, to accomplish the market demand, small market players utilize the partnership agreement strategy. It is predicted that these strategies are anticipated to escalate up the company revenue and its growth in the forecasted period. For instance, · In May 2020, AbbVie Inc. has completed its acquisition of Allergan. This acquisition has helped AbbVie Inc. to increase its market and demand for its product in the future as the acquisition has combined the product portfolio of the companies thereby strengthening their business · In October 2020, AbbVie Inc. has announced that it has entered into an agreement with Luminera. It is predicted that this agreement is anticipated to strengthen the company’s footprints in the aesthetic business sector · Revance has mentioned about the 3 clinical trial approved b FDA in March 2020 which belongs to aesthetic category. These will bring more dermal filler to the market CONCLUSION The dermal filler market size experienced a decline in 2020 due to increased restrictions imposed by various governments leading to the closing of non-emergent healthcare facilities including procedures such as aesthetic & cosmetic surgery devices and augmentation among more. The mass quarantined imposed by the government put stop to transportation, international travels, medical visa which is an important part of Thailand healthcare revenue and the dermal filler clinics have mentioned during primary research that the patient number has decreased due to covid-19 restrictions. The market player has experienced decreasing levels of customer demand for its products beginning in the second half of its first quarter of 2020. It can be concluded that the COVID 19 pandemic situation has an adverse impact on the global dermal filler market affecting the price, supply, and demand of the fillers. However, in the crisis call, market players, government bodies, and healthcare organizations work closely with healthcare professionals, customers, and patients for the betterment of public health.
Animal Treatment: High Country Humane looking ahead to 2024
The growth of the animal treatment market can be attributed to increasing government initiatives, which ensure maximum preventive healthcare in animals. A majority of the developed economies have norms that impel owners to have pet insurance.  On the basis of animal type, the animal treatment market is segmented into dogs, cats, pigs, poultry, cattle, and horses. The poultry segment will receive maximum veterinary care in the coming years. Earlier, the health of poultry was neglected to a greater extent. Chickens having underlying conditions were discarded without providing any veterinary treatment. However, with various animal cruelty acts in place, the mortality rate in poultry has decreased.   Download PDF Brochure With Latest Edition @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180479252 Based on the type of treatment, the animal treatment market is segmented into no medicalization, basic medicalization, and veterinary care. There has been a considerable decline in the percentage of animals receiving no medicalization, due to the rising awareness regarding the availability of reimbursement for veterinary services. As a result, owners have started prioritizing the health of their companion animals.  The number of dogs and cats receiving vaccination and treatment in these countries has increased. This trend is projected to continue until the end of 2024. Furthermore, in the case of livestock, animal welfare authorities have assigned diligent veterinarians for farms to assure maximum preventive healthcare. North America is the largest market in terms of the consumption of veterinary products. People are well versed with animal healthcare regulations, and hence high-quality care is provided to animals in this region. However, the animal treatment market has become saturated in the US, as the number of veterinary visits has stabilized. On the contrary, the animal treatment rate in European countries has increased. The increasing standard of living and the growing number of veterinarians providing exceptional medical services to animals are the major factors driving the European animal treatment market. Prominent players in the animal treatment market are Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), Abaxis (US), Virbac SA (France), IDEXX Laboratories, Inc. (US), Neogen Corporation (US), and Heska Corporation (US).
Increased Adoption of Refurbished Diagnostic Imaging Systems - Fluoroscopy Equipment
The market for fluoroscopy equipment is expected to grow from USD 5.9 billion in 2020 to USD 7.5 billion by 2025, at a CAGR of 4.8% during the forecast period. Growth in the fluoroscopy equipment market is attributed to factors such as the advantages of FPDs over image intensifiers, the use of fluoroscopy in pain management, reimbursement cuts for analog radiography systems, the rising geriatric population, and the growing prevalence of chronic diseases.  The COVID-19 pandemic has significantly impacted the buying capacity of hospitals, especially small-scale hospitals and scanning centers. According to an article in Livemint, private hospitals in India have faced revenue losses of up to 90% due to the COVID-19 pandemic. The pandemic has also impacted the operation of manufacturing companies.  The evolution of fluoroscopy systems and C-arms from traditional X-ray image intensifier technology to digital flat-panel detectors (FPDs) has brought about significant advancements in fluoroscopic imaging. FPDs have a number of advantages over image intensifiers, including compact sizes and reduced radiation dose. Systems with FPDs have the potential for higher image resolution than their predecessors.  FPDs offers no image distortion, greater sensitivity, and better patient coverage. Due to their advantages, many hospitals are now opting for FPD fluoroscopes. The growing preference for advanced technologies, and the need to shift to new, more efficient products, will be a key factors driving the growth of this market segment.  Download PDF Brochure With Latest Edition @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=23056341 Fluoroscopic procedures can result in high radiation dose exposure for complex procedures, such as stent placement. These procedures are time-consuming, which greatly increases the radiation that patients are exposed to and the risk of hazards such as radiation-induced injuries to the skin and underlying tissues. The long-term side-effects of prolonged radiation exposure can also include cancer. This has served to push users towards non-radiation modalities, particularly in the case of pediatric patients. For instance, the ACR (American College of Radiology) Appropriateness Criteria specify that for infants younger than two months, ultrasound should be considered before a fluoroscopic examination. Additionally, CT examinations can completely eliminate the need for a fluoroscopic examination, as a CT scan is noninvasive as opposed to minimally invasive fluoroscopic imaging.  Many hospitals in developing countries are unable to invest in fluoroscopy equipment due to their high costs, poor reimbursement rates, and budget constraints, and therefore prefer refurbished systems. These systems are less expensive than new systems—approximately 40% to 60% of the original price. Increasing demand for refurbished devices poses a major challenge to the sales of new instruments—and, subsequently, to the growth of market players and small manufacturers. Get Data as per your Format and Definition | REQUEST FOR CUSTOMIZATION: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=23056341 These systems come with a software package that helps store patient information. With the help of data integration, physicians can easily compare scans to effectively observe disease progression. To devise a treatment plan, clinicians are demanding access to integrated, comprehensive data on the patient’s diagnostic history. In addition to data integration, there lies a huge opportunity for making data available through mobile technologies. This will help doctors to view and study scans wherever they are. Due to their advantages, convenience, and huge demand from clinicians, data integrated systems offer a huge opportunity for market growth. The rising prevalence of cardiovascular diseases and the increasing number of orthopedic surgeries are some of the major factors driving the growth of the mobile C-arms market. C-arms are used for a wide range of applications, including surgeries for cardiovascular diseases, neurosurgeries, and surgeries for gastroenterology, orthopedics, traumatology, and urology disorders. Cardiology is the largest diagnostic application segment of the fluoroscopy equipment market. The large share of this segment is attributed to the high burden of cardiovascular diseases (CVDs) worldwide and the convenience and better results offered by fluoroscopy systems during the diagnosis and treatment of various cardiac disorders. Key Market Players The major players in the fluoroscopy equipment market are Siemens Healthineers (Germany), GE Healthcare (US), and Philips (Netherlands). These companies together accounted for a share of ~80% of the fluoroscopy equipment market in 2018. Other players in the market include Shimadzu Corporation (Japan), Ziehm Imaging GmbH (Germany), Toshiba Medical Systems Corporation (Japan), Hitachi Ltd. (Japan), Carestream Health, Inc. (US), Hologic, Inc. (US), Lepu Medical Technology Co., Ltd. (China), Agfa-Gevaert Group (Belgium), and ADANI Systems Inc. (Belarus) among others.